Patents by Inventor Dianne Sako

Dianne Sako has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TGF-BETA SUPERFAMILY TYPE I AND TYPE II RECEPTOR HETEROMULTIMERS AND USES THEREOF
    Publication number: 20160298093
    Abstract: In certain aspects, the disclosure provides soluble heteromeric polypeptide complexes comprising an extracellular domain of a type I serine/threonine kinase receptor of the TGF-beta family and an extracellular domain of a type II serine/threonine kinase receptor of the TGF-beta family. In some embodiments, the disclosure provides soluble polypeptide complexes comprising an extracellular domain of a type II receptor selected from: ActRIIA, ActRIIB, TGFBRII, BMPRII, and MISRII. In some embodiments, the disclosure provides soluble polypeptide complexes comprising an extracellular domain of a type I receptor selected from: ALK1, ALK2, ALK3, ALK4, ALK5, ALK6, and ALK7. Optionally the soluble complex is a heterodimer. In certain aspects, such soluble polypeptide complexes may be used to regulate (promote or inhibit) growth of tissues or cells including, for example, muscle, bone, cartilage, fat, neural tissue, tumors, cancerous cells, and/or cells of hematopoietic lineages, including red blood cells.
    Type: Application
    Filed: April 6, 2016
    Publication date: October 13, 2016
    Inventors: Ravindra Kumar, Asya Grinberg, Dianne Sako, Robert Scott Pearsall, Roselyne Castonguay
  • ALK4:ACTRIIB HETEROMULTIMERS AND USES THEREOF
    Publication number: 20160289292
    Abstract: In certain aspects, the disclosure provides soluble heteromeric polypeptide complexes comprising an extracellular domain of an ALK4 receptor and an extracellular domain of ActRIIB. In certain aspects, such soluble ALK4:ActRIIB complexes may be used to regulate (promote or inhibit) growth of tissues or cells including, for example, muscle, bone, cartilage, fat, neural tissue, tumors, and/or cancerous cells. In certain aspects, such ALK4:ActRIIB complexes are can be used to improve muscle formation, bone formation, metabolic parameters, and disorders associated with these tissues, cellular networks, kidney, and endocrine systems.
    Type: Application
    Filed: April 6, 2016
    Publication date: October 6, 2016
    Inventors: Ravindra Kumar, Asya Grinberg, Dianne Sako, Robert Scott Pearsall, Roselyne Castonguay
  • SINGLE-ARM TYPE I AND TYPE II RECEPTOR FUSION PROTEINS AND USES THEREOF
    Publication number: 20160289298
    Abstract: In certain aspects, the disclosure provides soluble single-arm heteromeric polypeptide complexes comprising an extracellular domain of a type I serine/threonine kinase receptor of the TGF-beta family or an extracellular domain of a type II serine/threonine kinase receptor of the TGF-beta family. In some embodiments, the disclosure provides soluble single-arm polypeptide complexes comprising an extracellular domain of a type II receptor selected from: ActRIIA, ActRIIB, TGFBRII, BMPRII, and MISRII. In some embodiments, the disclosure provides soluble single-arm polypeptide complexes comprising an extracellular domain of a type I receptor selected from: ALK1, ALK2, ALK3, ALK4, ALK5, ALK6, and ALK7. Optionally the soluble complex is a heterodimer.
    Type: Application
    Filed: April 6, 2016
    Publication date: October 6, 2016
    Inventors: Ravindra Kumar, Asya Grinberg, Dianne Sako
  • PLATELET GLYCOPROTEIN IB ALPHA VARIANT FUSION POLYPEPTIDES AND METHODS OF USE THEREOF
    Publication number: 20110039780
    Abstract: The present invention provides compositions and methods for treating or preventing vascular-associated disorders.
    Type: Application
    Filed: November 19, 2009
    Publication date: February 17, 2011
    Applicant: Wyeth
    Inventors: Gray Shaw, Dianne Sako, Ravindra Kumar, Jin Xu
  • Platelet glycoprotein Ib alpha variant fusion polypeptides and methods of use thereof
    Patent number: 7727535
    Abstract: The present invention provides compositions and methods for treating or preventing vascular-associated disorders.
    Type: Grant
    Filed: June 14, 2004
    Date of Patent: June 1, 2010
    Assignee: Wyeth
    Inventors: Gray Shaw, Dianne Sako, Ravindra Kumar, Jin Xu
  • Highly purified mocarhagin, a cobra venom protease, polynucleotides encoding same and related proteases, and therapeutic uses thereof
    Patent number: 7252820
    Abstract: Methods and compositions for treating a wide range of inflammatory diseases and disorders, and for inhibiting selectin-mediated binding by administering a mocarhagin protein, or fragments thereof with mocarhagin protein activity are provided. The mocarhagin protein may be administered alone, or in combination with a cytokine, lymphokine, or hematopoietic factor.
    Type: Grant
    Filed: February 25, 2005
    Date of Patent: August 7, 2007
    Assignee: Genetics Institute, LLC
    Inventors: Amechand Boodhoo, Jasbir S. Seehra, Gray Shaw, Dianne Sako
  • Platlet glycoprotein Ib alpha fusion polypeptides and methods of use thereof
    Publication number: 20060140935
    Abstract: The present invention provides compositions and methods for treating or preventing vascular-associated disorders.
    Type: Application
    Filed: October 24, 2005
    Publication date: June 29, 2006
    Applicant: Wyeth
    Inventors: Gray Shaw, Dianne Sako, Ravindra Kumar, Francis Sullivan, Tom McDonagh
  • Platelet glycoprotein Ib alpha fusion polypeptides and methods of use thereof
    Publication number: 20060093614
    Abstract: The present invention provides compositions and methods for treating or preventing vascular-associated disorders.
    Type: Application
    Filed: October 24, 2005
    Publication date: May 4, 2006
    Applicant: Wyeth
    Inventors: Gray Shaw, Dianne Sako, Ravindra Kumar, Francis Sullivan, Tom McDonagh
  • Highly purified mocarhagin, a cobra venom protease, polynucleotides encoding same and related proteases, and therapeutic uses thereof
    Publication number: 20050232914
    Abstract: Methods and compositions for treating a wide range of inflammatory diseases and disorders, and for inhibiting selectin-mediated binding by administering a mocarhagin protein, or fragments thereof with mocarhagin protein activity are provided. The mocarhagin protein may be administered alone, or in combination with a cytokine, lymphokine, or hematopoietic factor.
    Type: Application
    Filed: February 25, 2005
    Publication date: October 20, 2005
    Inventors: Amechand Boodhoo, Jasbir Seehra, Gray Shaw, Dianne Sako
  • Platelet glycoprotein Ib alpha variant fusion polypeptides and methods of use thereof
    Publication number: 20050089888
    Abstract: The present invention provides compositions and methods for treating or preventing vascular-associated disorders.
    Type: Application
    Filed: June 14, 2004
    Publication date: April 28, 2005
    Inventors: Gray Shaw, Dianne Sako, Ravindra Kumar, Jin Xu
  • Highly purified mocarhagin, a cobra venom protease, polynucleotides encoding same and related proteases, and therapeutic uses thereof
    Patent number: 6881404
    Abstract: Highly purified mocarhagin, a cobra venom protease, is disclosed. Pharmaceutical compositions and therapeutic uses of the highly purified protease are also provided. Polynucleotides encoding such protease and related proteases are also disclosed.
    Type: Grant
    Filed: November 27, 2001
    Date of Patent: April 19, 2005
    Assignee: Genetics Institute, LLC
    Inventors: Amechand Boodhoo, Jasbir S. Seehra, Gray Shaw, Dianne Sako
  • Highly purified mocarhagin, a cobra venom protease, polynucleotides encoding same and related proteases, and therapeutic uses thereof
    Publication number: 20020127691
    Abstract: Highly purified mocarhagin, a cobra venom protease, is disclosed. Pharmaceutical compositions and therapeutic uses of the highly purified protease are also provided. Polynucleotides encoding such protease and related proteases are also disclosed.
    Type: Application
    Filed: November 27, 2001
    Publication date: September 12, 2002
    Applicant: Genetics Institute, Inc.
    Inventors: Amechand Boodhoo, Jasbir S. Seehra, Gray Shaw, Dianne Sako
  • Highly purified mocarhagin cobra venom protease polynucleotides endcoding same and related proteases and therapeutic uses thereof
    Patent number: 6413760
    Abstract: Highly purified mocarhagin, a cobra venom protease, is disclosed. Pharmaceutical compositions and therapeutic uses of the highly purified protease are also provided. Polynucleotides encoding such protease and related proteases are also disclosed.
    Type: Grant
    Filed: February 18, 1998
    Date of Patent: July 2, 2002
    Assignee: Genetics Institute, Inc.
    Inventors: Amechand Boodhoo, Jasbir S. Seehra, Gray Shaw, Dianne Sako